文献速递临床试验与 GCP基础与转化研究

mRNA编码膜锚定HIV包膜三聚体疫苗接种在1期临床试验中诱导2级中和抗体

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial.
PubMed 文献 · Sci Transl Med · 2025-07-30

这项随机、开放标签1期临床试验评估了三种mRNA编码包膜三聚体的安全性和免疫原性。疫苗总体耐受良好,但6.5%(7/108)参与者出现荨麻疹。膜锚定三聚体较可溶性三聚体降低基底结合抗体频率,且80%接种者产生自体2级血清中和抗体,而可溶性三聚体组仅4%。

要点

  • mRNA编码膜锚定HIV包膜三聚体疫苗总体耐受良好,但6.5%(7/108)参与者出现荨麻疹。
  • 膜锚定三聚体较可溶性三聚体降低基底结合血清抗体频率。
  • 膜锚定三聚体组80%接种者产生自体2级血清中和抗体,可溶性三聚体组仅4%。

核心结论

  • mRNA编码膜锚定HIV包膜三聚体在1期临床试验中显示出更有利的安全性,并代表HIV疫苗临床开发的有前景平台。

研究设计与样本

  • 随机、开放标签1期临床试验,评估三种mRNA编码包膜三聚体(包括可溶性和膜锚定形式的两种剂量)的安全性和免疫原性。

主要发现

  • 疫苗总体耐受良好,但6.5%(7/108)参与者出现荨麻疹,比例高于其他mRNA疫苗。
  • mRNA编码三聚体诱导强烈的包膜特异性B细胞和T细胞反应。
  • 与可溶性三聚体相比,膜锚定三聚体免疫降低了基底结合血清抗体频率。
  • 膜锚定三聚体组80%接种者在三次免疫后产生自体2级血清中和抗体,而可溶性三聚体组仅4%。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

mRNA technology might accelerate development of an urgently needed preventive human immunodeficiency virus (HIV) vaccine. We evaluated the safety and immunogenicity of three mRNA-encoded envelope trimers, including two doses of soluble and membrane-anchored forms, in a randomized, open-label, phase 1 clinical trial. Vaccines were generally well tolerated, although 6.5% (7 of 108) of participants developed urticaria, a higher proportion than seen with other mRNA vaccines. mRNA-encoded trimers induced strong envelope-specific B and T cell responses. Immunization with membrane-anchored trimers, intended to obscure epitopes at the trimer base targeted by nonneutralizing antibodies, reduced the frequency of base-binding serum antibodies in comparison with soluble trimers. Three immunizations elicited autologous tier 2 serum neutralizing antibodies in 80% of vaccinees receiving the membrane-anchored trimers, in contrast to only 4% receiving the soluble trimer. Thus, with demonstration of more favorable safety, mRNA-encoded membrane-anchored HIV envelope trimers represent a promising platform for HIV vaccine clinical development.

来源:Sci Transl Med,查看原文。版权归原作者所有。

引用

  1. Parks KR, Moodie Z, Allen MA, et al. Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial. Sci Transl Med. 2025. PMID: 40737434. doi:10.1126/scitranslmed.ady6831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。